<DOC>
	<DOC>NCT01635387</DOC>
	<brief_summary>Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.</brief_summary>
	<brief_title>RAAS Inhibitor Drugs in Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>chronic kidney disease stage 5 undergoing maintenance haemodialysis for a minimum of 3 months existing arterial hypertension or history of arterial hypertension or resting blood pressure â‰¥140/90 mmHg or antihypertensive medication man and female 18 years and older. recent myocardial infarction (less than 3 months) atrial fibrillation/atrial flutter hypotension with systolic blood pressure of &lt;90 mmHg highgrade aortic stenosis left ventricular ejection fration &lt;50% known allergy to aliskiren severe disorders of liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>